284 related articles for article (PubMed ID: 15574200)
21. Promoter hypermethylation profile of RASSF1A, FHIT, and sFRP1 in intracranial primitive neuroectodermal tumors.
Chang Q; Pang JC; Li KK; Poon WS; Zhou L; Ng HK
Hum Pathol; 2005 Dec; 36(12):1265-72. PubMed ID: 16311119
[TBL] [Abstract][Full Text] [Related]
22. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
23. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.
Iliopoulos D; Guler G; Han SY; Johnston D; Druck T; McCorkell KA; Palazzo J; McCue PA; Baffa R; Huebner K
Oncogene; 2005 Feb; 24(9):1625-33. PubMed ID: 15674328
[TBL] [Abstract][Full Text] [Related]
24. Silencing of imprinted CDKN1C gene expression is associated with loss of CpG and histone H3 lysine 9 methylation at DMR-LIT1 in esophageal cancer.
Soejima H; Nakagawachi T; Zhao W; Higashimoto K; Urano T; Matsukura S; Kitajima Y; Takeuchi M; Nakayama M; Oshimura M; Miyazaki K; Joh K; Mukai T
Oncogene; 2004 May; 23(25):4380-8. PubMed ID: 15007390
[TBL] [Abstract][Full Text] [Related]
25. Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach.
Schildhaus HU; Kröckel I; Lippert H; Malfertheiner P; Roessner A; Schneider-Stock R
Int J Oncol; 2005 Jun; 26(6):1493-500. PubMed ID: 15870861
[TBL] [Abstract][Full Text] [Related]
26. [Hypermethylation of fragile histidine triad gene and 3p14 allelic deletion in ovarian carcinomas].
Hong FZ; Wang B; Li HM; Liew CT
Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):257-61. PubMed ID: 16181544
[TBL] [Abstract][Full Text] [Related]
27. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.
Sathyanarayana UG; Padar A; Huang CX; Suzuki M; Shigematsu H; Bekele BN; Gazdar AF
Clin Cancer Res; 2003 Dec; 9(17):6389-94. PubMed ID: 14695139
[TBL] [Abstract][Full Text] [Related]
28. Promoter methylation status of the FHIT gene and Fhit expression: association with HER2/neu status in breast cancer patients.
Jeong YJ; Jeong HY; Lee SM; Bong JG; Park SH; Oh HK
Oncol Rep; 2013 Nov; 30(5):2270-8. PubMed ID: 23969757
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic inactivation of the RUNX3 gene in lung cancer.
Sato K; Tomizawa Y; Iijima H; Saito R; Ishizuka T; Nakajima T; Mori M
Oncol Rep; 2006 Jan; 15(1):129-35. PubMed ID: 16328045
[TBL] [Abstract][Full Text] [Related]
30. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of growth of mouse gastric cancer cells by Runx3, a novel tumor suppressor.
Guo WH; Weng LQ; Ito K; Chen LF; Nakanishi H; Tatematsu M; Ito Y
Oncogene; 2002 Nov; 21(54):8351-5. PubMed ID: 12447699
[TBL] [Abstract][Full Text] [Related]
32. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
[TBL] [Abstract][Full Text] [Related]
33. Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues.
Matsubayashi H; Sato N; Fukushima N; Yeo CJ; Walter KM; Brune K; Sahin F; Hruban RH; Goggins M
Clin Cancer Res; 2003 Apr; 9(4):1446-52. PubMed ID: 12684418
[TBL] [Abstract][Full Text] [Related]
34. Reduced acetylated histone H4 is associated with promoter methylation of the fragile histidine triad gene in resected esophageal squamous cell carcinoma.
Tzao C; Sun GH; Tung HJ; Hsu HS; Hsu WH; Wang YC; Cheng YL; Lee SC
Ann Thorac Surg; 2006 Aug; 82(2):396-401; discussion 401. PubMed ID: 16863736
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas.
Goldberg M; Rummelt C; Laerm A; Helmbold P; Holbach LM; Ballhausen WG
Br J Dermatol; 2006 Dec; 155(6):1154-8. PubMed ID: 17107382
[TBL] [Abstract][Full Text] [Related]
36. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future.
Esteller M
Oncogene; 2002 Aug; 21(35):5427-40. PubMed ID: 12154405
[TBL] [Abstract][Full Text] [Related]
37. Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines.
Ku JL; Kang SB; Shin YK; Kang HC; Hong SH; Kim IJ; Shin JH; Han IO; Park JG
Oncogene; 2004 Sep; 23(40):6736-42. PubMed ID: 15273736
[TBL] [Abstract][Full Text] [Related]
38. Evidence of a role for the INK4 family of cyclin-dependent kinase inhibitors in ovarian granulosa cell tumors.
Arcellana-Panlilio MY; Egeler RM; Ujack E; Magliocco A; Stuart GC; Robbins SM; Coppes MJ
Genes Chromosomes Cancer; 2002 Oct; 35(2):176-81. PubMed ID: 12203782
[TBL] [Abstract][Full Text] [Related]
39. RUNX3 gene methylation in epithelial ovarian cancer tissues and ovarian cancer cell lines.
Zhang S; Wei L; Zhang A; Zhang L; Yu H
OMICS; 2009 Aug; 13(4):307-11. PubMed ID: 19645591
[TBL] [Abstract][Full Text] [Related]
40. Promoter hypermethylation of MGMT, CDH1, RAR-beta and SYK tumour suppressor genes in granulosa cell tumours (GCTs) of ovarian origin.
Dhillon VS; Young AR; Husain SA; Aslam M
Br J Cancer; 2004 Feb; 90(4):874-81. PubMed ID: 14970867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
